罗氏与GBT就inclacumab签署了协议

2018-08-25 MedSci MedSci原创

罗氏公司已将inclacumab的权利出售给Global Blood Therapeutics,后者计划开发治疗镰状细胞病(SCD)患者的血管闭塞性危象(VOC)。根据协议条款,GBT将负责全球单克隆抗体的所有开发,制造和商业化。作为回报,罗氏将获得200万美元的预付款,并且还可以为镰状细胞疾病适应症以及基于销售的特许权使用费提供高达1.25亿美元的开发和商业化里程碑付款。这家瑞士制药巨头一直在研



罗氏公司已将inclacumab的权利出售给Global Blood Therapeutics,后者计划开发治疗镰状细胞病(SCD)患者的血管闭塞性危象(VOC)。

根据协议条款,GBT将负责全球单克隆抗体的所有开发,制造和商业化。

作为回报,罗氏将获得200万美元的预付款,并且还可以为镰状细胞疾病适应症以及基于销售的特许权使用费提供高达1.25亿美元的开发和商业化里程碑付款。

这家瑞士制药巨头一直在研发用于治疗冠状动脉疾病的药物,但在二期试验后被放弃。然而,GBT计划利用罗氏之前的临床研究得出的安全数据,因为它在SCD中具有优势。

Inclacumab是一种新型的全人单克隆抗体,旨在抑制P-选择素,这是一种在内皮细胞和血小板上发现的粘附分子,有助于促进VOC发展过程中的细胞 - 细胞相互作用。

"Inclacumab是voxelotor的理想补充,我们的主要研究是口服,每日一次的治疗,用于SCD的III期临床开发。与voxelotor一样,inclacumab具有强大的科学依据,并且有可能为SCD患者提供显着的临床益处,"GBT总裁兼首席执行官Ted Love解释了该交易背后的理由。


此文系梅斯医学(MedSci)原创整理编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1933982, encodeId=368d193398242, content=<a href='/topic/show?id=6659981920' target=_blank style='color:#2F92EE;'>#inclacumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9819, encryptionId=6659981920, topicName=inclacumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=284b425, createdName=zll0625, createdTime=Fri Jan 25 19:26:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912025, encodeId=4ab01912025f1, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Apr 18 20:26:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341685, encodeId=9aa8341685e6, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Aug 30 04:13:02 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340733, encodeId=d85a340e33bc, content=谢谢分享,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Sat Aug 25 10:19:03 CST 2018, time=2018-08-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1933982, encodeId=368d193398242, content=<a href='/topic/show?id=6659981920' target=_blank style='color:#2F92EE;'>#inclacumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9819, encryptionId=6659981920, topicName=inclacumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=284b425, createdName=zll0625, createdTime=Fri Jan 25 19:26:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912025, encodeId=4ab01912025f1, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Apr 18 20:26:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341685, encodeId=9aa8341685e6, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Aug 30 04:13:02 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340733, encodeId=d85a340e33bc, content=谢谢分享,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Sat Aug 25 10:19:03 CST 2018, time=2018-08-25, status=1, ipAttribution=)]
    2019-04-18 snf701207
  3. [GetPortalCommentsPageByObjectIdResponse(id=1933982, encodeId=368d193398242, content=<a href='/topic/show?id=6659981920' target=_blank style='color:#2F92EE;'>#inclacumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9819, encryptionId=6659981920, topicName=inclacumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=284b425, createdName=zll0625, createdTime=Fri Jan 25 19:26:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912025, encodeId=4ab01912025f1, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Apr 18 20:26:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341685, encodeId=9aa8341685e6, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Aug 30 04:13:02 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340733, encodeId=d85a340e33bc, content=谢谢分享,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Sat Aug 25 10:19:03 CST 2018, time=2018-08-25, status=1, ipAttribution=)]
    2018-08-30 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1933982, encodeId=368d193398242, content=<a href='/topic/show?id=6659981920' target=_blank style='color:#2F92EE;'>#inclacumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9819, encryptionId=6659981920, topicName=inclacumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=284b425, createdName=zll0625, createdTime=Fri Jan 25 19:26:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912025, encodeId=4ab01912025f1, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Apr 18 20:26:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341685, encodeId=9aa8341685e6, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Aug 30 04:13:02 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340733, encodeId=d85a340e33bc, content=谢谢分享,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Sat Aug 25 10:19:03 CST 2018, time=2018-08-25, status=1, ipAttribution=)]
    2018-08-25 liumin1987

    谢谢分享,学习了。

    0

相关资讯

ACC 2013:P-选择素拮抗剂inclacumab可减少NSTEMI患者心肌损伤

近日报道的一项小规模、2期研究——SELECT-ACS试验结果令人振奋,提示P-选择素拮抗剂inclacumab可能减少接受PCI的非ST段抬高心肌梗死患者的心肌损伤,该研究的主要终点是检测生物标志物。该研究结果在第62届美国心脏病学会年会(ACC2013)的最新临床试验分会场上公布,同时在线发表于美国心脏病学会杂志上[Results of the SELECT-ACS Trial.pdf]。Je